Shares of Sage Therapeutics <a href="https://www.reuters.com/markets/companies/SAGE.O" target="_blank">(SAGE.O)</a> slumped to a record low on Monday after the U.S. health regulator approved the company and partner Biogen's <a href="https://www.reuters.com/ma…